ERBB2 and breast carcinoma: Additionally, a small retrospective case series reported that patients with leptomeningeal metastases from HER2‐positive breast cancer experienced neurological benefits from the neratinib and capecitabine combination, with a median duration of neurological response of 6.5 months [34].